Precision Proteomics is a pre-clinical stage biotechnology company commercializing a novel platform for the development of next-generation precision medicines. Precision was created to apply cutting-edge proteomics to the development and clinical utilization of therapeutics. Precision’s technology can systematically and quantitatively profile activations of key signal pathways that drive pathogenesis and the development of resistance to therapy. The company is actively building research and development partnerships with biopharmaceutical companies globally in respect of approved and emerging therapies, and will at the same time advance proprietary programs based on its discovery of novel therapeutic targets in certain cancers with high unmet need. Precision is based in Toronto, Ontario and has offices in London, Ontario and Hong Kong, China.